Pnd56 - A Cost-Effectiveness Analysis Using Real-World Data From the Msbase Registry: Comparing Natalizumab to Fingolimod in Patients With Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Spain

Value in Health - United Kingdom

doi 10.1016/j.jval.2018.09.2022